Compare iShares Silver Trust (SLV) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Silver Trust vs BIO-TECHNE Corp — how do they compare? iShares Silver Trust trades at $58.54, while BIO-TECHNE Corp trades at $72.06 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while iShares Silver Trust pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| SLV | TECH | |
|---|---|---|
52-Week High | $105.57 | $72.29 |
52-Week Low | $33.89 | $43.31 |
Market Cap | — | $11.24B |
Sector | — | Health |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLV (iShares Silver Trust) trades at $57.50, up 2.95% with a bullish technical signal supported by moving averages. The ETF provides direct exposure to physical silver, which has seen volatile trading after a 50% decline from early 2026 highs. Recent price action shows silver rebounding amid Fed policy uncertainty and strong industrial demand fundamentals.
Silver's outlook remains compelling due to constrained supply and growing industrial demand, though high volatility and Fed policy sensitivity pose risks. The current technical setup suggests potential for continued upside if silver maintains support above $56, with resistance near $59.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
